{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:51:11Z","timestamp":1777701071443,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T00:00:00Z","timestamp":1508457600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10157-017-1475-9","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T01:03:08Z","timestamp":1508461388000},"page":"550-561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-3435","authenticated-orcid":false,"given":"Satoshi","family":"Minami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Mizui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,20]]},"reference":[{"key":"1475_CR1","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"1475_CR2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323\u20136.","journal-title":"Nat Med"},{"key":"1475_CR3","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","volume":"16","author":"X Wang","year":"2005","unstructured":"Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846\u201351.","journal-title":"J Am Soc Nephrol"},{"key":"1475_CR4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1681\/ASN.2008010021","volume":"19","author":"J Perucca","year":"2008","unstructured":"Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol. 2008;19:1721\u201331.","journal-title":"J Am Soc Nephrol"},{"key":"1475_CR5","doi-asserted-by":"crossref","first-page":"F46","DOI":"10.1152\/ajprenal.2000.279.1.F46","volume":"279","author":"CA Ecelbarger","year":"2000","unstructured":"Ecelbarger CA, Kim GH, Terris J, Masilamani S, Mitchell C, Reyes I, et al. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol. 2000;279:F46\u201353.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1475_CR6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01868594","volume":"120","author":"A Sun","year":"1991","unstructured":"Sun A, Grossman EB, Lombardi M, Hebert SC. Vasopressin alters the mechanism of apical Cl\u2212 entry from Na+:Cl\u2212 to Na+:K+:2Cl\u2212 cotransport in mouse medullary thick ascending limb. J Membr Biol. 1991;120:83\u201394.","journal-title":"J Membr Biol"},{"key":"1475_CR7","doi-asserted-by":"crossref","first-page":"243s","DOI":"10.1111\/j.1469-445X.2000.tb00029.x","volume":"85","author":"LT Bankir","year":"2000","unstructured":"Bankir LT, Trinh-Trang-Tan MM. Renal urea transporters Direct and indirect regulation by vasopressin. Exp Physiol. 2000;85:243s\u201352s.","journal-title":"Exp Physiol"},{"issue":"Suppl 1","key":"1475_CR8","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s10557-011-6299-3","volume":"25","author":"SR Kim","year":"2011","unstructured":"Kim SR, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S5\u201317.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1475_CR9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijcard.2014.08.147","volume":"177","author":"K Kajimoto","year":"2014","unstructured":"Kajimoto K, Abe T. Blood urea nitrogen as a marker of the acute response to addition of tolvaptan to standard therapy in patients hospitalized for acute heart failure syndromes. Int J Cardiol. 2014;177:589\u201391.","journal-title":"Int J Cardiol"},{"key":"1475_CR10","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4330\/wjc.v6.i12.1252","volume":"6","author":"NA Gilotra","year":"2014","unstructured":"Gilotra NA, Russell SD. Arginine vasopressin as a target in the treatment of acute heart failure. World J Cardiol. 2014;6:1252\u201361.","journal-title":"World J Cardiol"},{"key":"1475_CR11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319\u201331.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"1475_CR12","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan I. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33\u201345.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1475_CR13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients. Circ J. 2013;77:397\u2013404.","journal-title":"Circ J"},{"key":"1475_CR14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00774-004-0547-6","volume":"23","author":"Y Nishizawa","year":"2005","unstructured":"Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab. 2005;23:97\u2013104.","journal-title":"J Bone Miner Metab"},{"key":"1475_CR15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E Elm von","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573\u20137.","journal-title":"Ann Intern Med"},{"key":"1475_CR16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s10157-014-0949-2","volume":"18","author":"Japanese Society of Nephrology","year":"2014","unstructured":"Japanese Society of Nephrology. Evidence-based Clinical Practice Guideline for CKD 2013. Clin Exp Nephrol. 2014;18:346\u2013423.","journal-title":"Clin Exp Nephrol"},{"key":"1475_CR17","first-page":"33","volume":"29","author":"T Mori","year":"2013","unstructured":"Mori T, Oba I, Koizumi K, Kodama M, Shimanuki M, Tanno M, et al. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis. Adv Perit Dial. 2013;29:33\u20137.","journal-title":"Adv Perit Dial"},{"key":"1475_CR18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ckj\/sfv124","volume":"9","author":"B Afsar","year":"2016","unstructured":"Afsar B, Ortiz A, Covic A, Solak Y, Goldsmith D, Kanbay M. Focus on renal congestion in heart failure. Clin Kidney J. 2016;9:39\u201347.","journal-title":"Clin Kidney J."},{"key":"1475_CR19","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1681\/ASN.2008080882","volume":"20","author":"RW Schrier","year":"2009","unstructured":"Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2009;20:1888\u201393.","journal-title":"J Am Soc Nephrol"},{"key":"1475_CR20","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2255\u201366.","journal-title":"N Engl J Med"},{"key":"1475_CR21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","volume":"142","author":"MJ Sarnak","year":"2005","unstructured":"Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342\u201351.","journal-title":"Ann Intern Med"},{"key":"1475_CR22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neurad.2007.11.004","volume":"35","author":"GJ Rinkel","year":"2008","unstructured":"Rinkel GJ. Natural history, epidemiology and screening of unruptured intracranial aneurysms. J Neuroradiol. 2008;35:99\u2013103.","journal-title":"J Neuroradiol"},{"key":"1475_CR23","doi-asserted-by":"crossref","first-page":"F881","DOI":"10.1152\/ajprenal.00367.2004","volume":"288","author":"B Yang","year":"2005","unstructured":"Yang B, Bankir L. Urea and urine concentrating ability: new insights from studies in mice. Am J Physiol Renal Physiol. 2005;288:F881\u201396.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1475_CR24","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1681\/ASN.2005010031","volume":"16","author":"RA Fenton","year":"2005","unstructured":"Fenton RA, Flynn A, Shodeinde A, Smith CP, Schnermann J, Knepper MA. Renal phenotype of UT-A urea transporter knockout mice. J Am Soc Nephrol. 2005;16:1583\u201392.","journal-title":"J Am Soc Nephrol"},{"key":"1475_CR25","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332\u201343.","journal-title":"JAMA"},{"key":"1475_CR26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1681\/ASN.2012030254","volume":"24","author":"RA Koeth","year":"2013","unstructured":"Koeth RA, Kalantar-Zadeh K, Wang Z, Fu X, Tang WH, Hazen SL. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol. 2013;24:853\u201361.","journal-title":"J Am Soc Nephrol"},{"key":"1475_CR27","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/ki.2014.429","volume":"87","author":"C Drechsler","year":"2015","unstructured":"Drechsler C, Kalim S, Wenger JB, Suntharalingam P, Hod T, Thadhani RI, et al. Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease. Kidney Int. 2015;87:1201\u20138.","journal-title":"Kidney Int"},{"key":"1475_CR28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2014.04.034","volume":"64","author":"S Kalim","year":"2014","unstructured":"Kalim S, Karumanchi SA, Thadhani RI, Berg AH. Protein carbamylation in kidney disease: pathogenesis and clinical implications. Am J Kidney Dis. 2014;64:793\u2013803.","journal-title":"Am J Kidney Dis"},{"key":"1475_CR29","doi-asserted-by":"crossref","first-page":"e82506","DOI":"10.1371\/journal.pone.0082506","volume":"8","author":"C Pietrement","year":"2013","unstructured":"Pietrement C, Gorisse L, Jaisson S, Gillery P. Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD. PLoS One. 2013;8:e82506.","journal-title":"PLoS One"},{"key":"1475_CR30","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1073\/pnas.0401704101","volume":"101","author":"RA Fenton","year":"2004","unstructured":"Fenton RA, Chou CL, Stewart GS, Smith CP, Knepper MA. Urinary concentrating defect in mice with selective deletion of phloretin-sensitive urea transporters in the renal collecting duct. Proc Natl Acad Sci USA. 2004;101:7469\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1475_CR31","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/ki.2013.62","volume":"83","author":"F Li","year":"2013","unstructured":"Li F, Lei T, Zhu J, Wang W, Sun Y, Chen J, et al. A novel small-molecule thienoquinolin urea transporter inhibitor acts as a potential diuretic. Kidney Int. 2013;83:1076\u201386.","journal-title":"Kidney Int"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-017-1475-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-017-1475-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-017-1475-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T13:57:50Z","timestamp":1526479070000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-017-1475-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,20]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1475"],"URL":"https:\/\/doi.org\/10.1007\/s10157-017-1475-9","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,20]]}}}